![]() |
|
|
Vol. 28, Issue 10, 1238-1243, October 2000
Graduate School of Pharmaceutical Sciences, University of Tokyo,
Tokyo, Japan (I.K., Y.K., H.S., M.A., K.I., Y.S.); and Gentest
Corporation, Woburn, Massachusetts (C.L.C.)
Our previous report showed that L754.394 and valspodar (PSC833) are
potent inhibitors of midazolam hydroxylation in human jejunum
microsomes and vectorial transport of vinblastine in Caco-2 cells,
respectively. In the present study, to directly examine the
interactions of these compounds as well as other substrates with CYP3A4
and P-glycoprotein (P-gp), we performed in vitro inhibition studies
using recombinant CYP3A4-expressed microsomes and an MDR1-transfected cell line, LLC-MDR1, respectively. In CYP3A4-expressed microsomes, both
L754.394 and ketoconazole, at a concentration less than 0.5 µM, are
the most potent inhibitors of the formation of 1'-hydroxymidazolam, a
major metabolite of midazolam formed by CYP3A4. The greatest inhibitory
effect on the transcellular transport of digoxin in LLC-MDR1 cells was
observed in the presence of valspodar (<0.1 µM), followed by
verapamil. From a comparison of the IC50 values, it
was shown that L754.394 and valspodar exhibited the highest selectivity
for CYP3A4 and P-gp, respectively. To demonstrate such specificity,
both midazolam hydroxylation and digoxin transport were observed in
CYP3A4 transfected Caco-2 cells, which coexpress both P-gp and CYP3A4,
in the presence or absence of L754.394 (0.5 µM) and valspodar (1.0 µM). L754.394 almost completely inhibited midazolam hydroxylation,
but not digoxin transport, whereas almost complete inhibition of
digoxin transport was observed in the presence of valspodar, but
inhibition of the hydroxylation was minimal. Thus, the present study
has demonstrated that L754.394 has a specific inhibitory effect on
CYP3A4, whereas valspodar is specific for P-gp.
This article has been cited by other articles:
![]() |
Y.-J. Lee, J. Maeda, H. Kusuhara, T. Okauchi, M. Inaji, Y. Nagai, S. Obayashi, R. Nakao, K. Suzuki, Y. Sugiyama, et al. In Vivo Evaluation of P-glycoprotein Function at the Blood-Brain Barrier in Nonhuman Primates Using [11C]Verapamil J. Pharmacol. Exp. Ther., February 1, 2006; 316(2): 647 - 653. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Mizuno, T. Niwa, Y. Yotsumoto, and Y. Sugiyama Impact of Drug Transporter Studies on Drug Discovery and Development Pharmacol. Rev., September 1, 2003; 55(3): 425 - 461. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Shitara, T. Itoh, H. Sato, A. P. Li, and Y. Sugiyama Inhibition of Transporter-Mediated Hepatic Uptake as a Mechanism for Drug-Drug Interaction between Cerivastatin and Cyclosporin A J. Pharmacol. Exp. Ther., February 1, 2003; 304(2): 610 - 616. [Abstract] [Full Text] [PDF] |
||||